Bothell biotech Curevo Vaccine names new chief medical officer
The vaccine maker raised $86 million last year and has now hired someone with experience in commercializing drugs.
Guy De La Rosa, chief medical officer of Curevo Vaccine in Bothell, Washington has been appointed as the company's shingles vaccine manufacturer.
The biotech company announced the hiring earlier this month. De La Rosa joins Curevo after joining Enanta Pharmaceuticals in Boston, Massachusetts. His most recent position was Executive Medical Director for Infectious Diseases.
George Simeon said, Curevo CEO, that the team was excited to welcome Dr. De La Rosa. Guy, with his more than 20 years' experience in clinical trials for infectious diseases, will have a positive effect on the company.
De La Rosa, who is a senior medical director at Takeda in Japan, spent over two years as a senior medical director at Takeda before joining Enanta. Prior to Takeda, he worked for Johnson & Johnson’s pharmaceutical division Janssen for about 11 years.
De La Rosa earned his M.D. Curevo stated that De La Rosa completed his residency at Boston's Massachusetts General Hospital and the University of Panama School of Medicine.
Curevo was founded in 2017 and is currently developing a vaccine against shingles called CRV-1001. According to the company, 678 people are currently participating in phase 2 of the vaccine's clinical trials. Curevo also investigates the use of the vaccine to protect immunocompromised kids against chickenpox. The South Korean-based Mogam Institute for Biomedical Research is helping the biotech develop its vaccines.
De La Rosa stated in a press release that the team was incredibly productive and they were developing a promising vaccine. I am excited to work with them all to get CRV 101 into use as soon as possible.